Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 64

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 64
---
    Target
    Market/Indications 
  
    bfLEAP™ – AI/ML platform for analysis of
    preclinical and clinical data
     
    AI/ML analytics platform
    derived from technology developed at JHU-APL and licensed by the Company.
     
    Biotechnology and pharmaceutical
    companies and other organizations.

    siRNA
     
    Small interfering RNA targeting
    Beta2-spectrin in the treatment of human diseases developed at George Washington University and licensed by the Company. Product
    has not yet initiated clinical testing.
     
    Hepatocellular carcinoma,
    treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

    Mebendazole 
     
    Improved formulation of
    Mebendazole developed at Johns Hopkins University and licensed by the Company. Product has begun the process of clinical testing
    but has not received regulatory approval for commercialization.
     
    Glioblastoma. 

On
January 14, 2022, the Company entered into an exclusive, worldwide, royalty-bearing license from George Washington University (“GWU”)
for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (“HCC”).
The license covers methods claimed in three U.S. and worldwide patent applications, and also includes use of this approach for treatment
of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. This program is currently in the preclinical stage
of development. The Company initiated proof-of-concept studies on this asset and will use the outcome of these studies to inform a clinical
development plan that would include initiation of IND-enabling studies.

 7 

Metabolic
dysfunction-associated steatotic liver disease (known as MASLD, which until recently was called non-alcoholic fatty liver disease, or
NAFLD) is a condition in which excess lipids, or fat, build up in the liver. This condition, which is more common in people who have
obesity and related metabolic diseases including type 2 diabetes, affects as many as 24% of adults in the United States and is associated
with risk of progression to more serious conditions, including metabolic dysfunction-associated steatohepatitis (“MASH”), with associated
liver inflammation and fibrosis, and HCC. Evidence in animal models of obesity suggest that a protein called β2-spectrin may